# What the FDA's GLP-1 Warning Letters Say About This Market

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/what-186-fda-warning-letters-say

> Two letters in 2023, ten in 2024, 72 in 2025. The most common subject is unlawful sale to consumers: enforcement here is overwhelmingly about what sellers said, not what pharmacies made.

## Key points

- 157 letters: 2 in 2023, 10 in 2024, 72 in 2025, 73 so far in 2026.
- 54 concern unlawful SALE and 59 false claims; only 8 are about adulterated products from compounding pharmacies.
- 57 are matched to a seller we review, covering roughly one in eleven of the sellers we track.
- We also found four of our own reviews crediting companies with letters they do not have. Fixed and disclosed.

We keep a register of FDA warning letters relevant to this market: **157** of them at our last count, on September 30, 2026. Read by year, it describes a regulator that went from occasional interest to sustained enforcement in about eighteen months: two letters in 2023, ten in 2024, **72 in 2025**, and 73 in 2026 through mid-September, with the year not finished.

Enforcement did not stop at our count. FDA has since posted two more GLP-1 letters, dated September 23 and 24, 2026, each to a website it says was introducing unapproved and misbranded injectable semaglutide into interstate commerce.[2][3] Neither is in the figures below. Both fit the pattern they describe.

## What the letters are about

*Most common subjects across 157 letters in our enforcement register.*

| Subject | Letters |
| --- | --- |
| Unlawful sale of unapproved and misbranded drugs to US consumers | 54 |
| False and misleading claims / misbranded | 34 |
| False and misleading claims / misbranded (telehealth) | 25 |
| Compounded GLP-1 marketing and labeling concerns | 12 |
| Compounding pharmacy / adulterated drug products | 8 |

The distribution is the interesting part. The single most common category is *selling* (unlawful sale of unapproved and misbranded drugs to consumers), not manufacturing failure. Add the two misbranding categories and the marketing one, and the overwhelming majority of enforcement in this market is about **what sellers said** rather than what pharmacies made. Research-chemical peptide sites are a clear case: [FDA’s letters to peptide sellers](https://glpwatchdog.org/research/fda-warning-letters-to-peptide-sellers) quote their disclaimers and set them aside.

> Fifty-four letters concern unlawful sale to consumers. Eight concern adulterated products from compounding pharmacies.

That matches what we find reading seller sites, and it matters to a buyer: the failure this market is being disciplined for is claims, not contamination. Our articles on [checking a review score](https://glpwatchdog.org/research/how-to-check-a-sellers-review-score) and [what a badge tells you](https://glpwatchdog.org/research/what-a-legitscript-badge-tells-you) cover the consumer end of the same problem.

Reading the letters to sellers in our register shows how specific the claims cases are. [MyStart Health](https://glpwatchdog.org/reviews/mystart-health), [TRYM Health](https://glpwatchdog.org/reviews/trym-health) and [Tuyo Health](https://glpwatchdog.org/reviews/tuyo-health) each received an FDA warning letter over false or misleading claims about compounded GLP-1s on their own websites. The letter to [Lyfe Rx](https://glpwatchdog.org/reviews/lyfe-rx) quotes “Clinically Proven Weight Loss” as a claim that implied its compounded products were the same as approved drugs. [Zeuss](https://glpwatchdog.org/reviews/zeuss) and [Harper Meds](https://glpwatchdog.org/reviews/harper-meds) were each cited for product labels bearing their own name, as if they had compounded the drug.

[Bioverse](https://glpwatchdog.org/reviews/bioverse) is another seller in the register with a letter of its own: the FDA reviewed its website and found its claims about compounded semaglutide and tirzepatide false or misleading.

The wording FDA objects to also turns up on sites that have no letter. The semaglutide FAQ at [Madison Meds](https://glpwatchdog.org/reviews/madison-meds) says its compounded drug “contains the same active ingredient as Ozempic”, the phrasing FDA cited in 2025 letters to other sellers. [Skinny Me America](https://glpwatchdog.org/reviews/skinny-me-america) calls its custom-blended semaglutide with B6 and B12 “FDA-approved”. A homepage badge at [Tennessee Trim Clinic](https://glpwatchdog.org/reviews/tennessee-trim-clinic) calls its compounded medications “FDA-Approved” too, and [Your Infinity Health](https://glpwatchdog.org/reviews/your-infinity-health) says its compounded GLP-1s are produced in “FDA approved facilities”.

[MEDVi](https://glpwatchdog.org/reviews/medvi) has one too. The FDA said the labels pictured on its website implied that MEDVi compounds the drugs itself, which it does not.

The pharmacy letters read differently. The one sent to [Empower Pharmacy](https://glpwatchdog.org/reviews/empower-pharmacy), a Houston compounder that supplies clinics and telehealth sellers, followed an inspection of its 503A facility and found compounded drugs that were essentially copies of commercially available products, tirzepatide and semaglutide among them, along with production deficiencies. That is a statement about what was made, not what was said.

## How many of them are sellers you could buy from

Fifty-seven of the 157 letters are matched to a seller we review. They cover 57 sellers, run by 54 operating companies, and five of those sellers have since closed. That is roughly one in eleven of the sellers we track: a meaningful minority, not a fringe.

> **A letter discloses a problem. It does not disqualify a seller.** A warning letter is the FDA telling a company to fix something, not a finding that its product harmed anyone, and companies do fix things. What a letter gives you is a specific, dated, official account of what the agency objected to, which is far more useful than a rating. Read what it alleges, then decide.

## An error of our own, in the same data

While assembling these figures we found that four of our own seller reviews were stating “4”, “5” and “6 FDA warning letters matched to this operator”, and that none of those four companies had a single letter in the register.

The cause was mundane and the consequence was not. The field holding letters had also been used, historically, to store general FDA-related notes: boilerplate along the lines of “compounded semaglutide is not FDA-approved and has not been evaluated by FDA”, which is true of every compounded product and is not a letter. The page counted the length of that list. Four named businesses were publicly credited with enforcement history they do not have.

It is corrected, an automated check now fails our build if a letter count is ever built from anything other than a letter, and we confirmed the fix did not create the opposite error. Those four reviews now say the company has no letter, which is true of them in the register. We are describing it here because an article about other people’s enforcement records that quietly omitted our own mistake would not be worth publishing.

## How to read a letter if your seller has one

1. **Check the date.** A 2023 letter about claims that have since changed is a different thing from one issued last quarter.
2. **Read the subject line.** “Adulterated drug products” and “false and misleading claims” are not the same order of concern.
3. **Check who it was addressed to.** Letters go to legal entities, which frequently operate several consumer brands (see [who actually runs your brand](https://glpwatchdog.org/research/who-actually-runs-your-glp1-brand)). The letter about [Fifty 410](https://glpwatchdog.org/reviews/fifty-410), for example, is addressed to its operator, Aspen Aesthetics.
4. **Look for what changed afterward.** The point of a warning letter is compliance, and the useful question is whether the company complied.
5. **Read it yourself.** Every letter is published by the FDA, and our [warning letters page](https://glpwatchdog.org/fda-warning-letters) links each one to its source.

## Frequently asked questions

### How many FDA warning letters have been issued in this market?

Our register held 157 at its last count, on September 30, 2026. By year: two in 2023, ten in 2024, 72 in 2025 and 73 in 2026 through mid-September. FDA has issued more since, including two GLP-1 letters to websites selling injectable semaglutide, dated September 23 and 24, 2026. Enforcement went from occasional to sustained in about eighteen months.

### What are most of the letters about?

Selling and saying, not manufacturing. The most common subject is unlawful sale of unapproved and misbranded drugs to US consumers, at 54 letters, followed by false and misleading claims. Only eight are about adulterated products from compounding pharmacies, and fewer than one in ten name adulterated drugs in their subject line at all.

### Does a warning letter mean a seller is dangerous?

No. It means the FDA told a company to fix something, and companies do fix things. A letter discloses a specific, dated, official objection, which is more useful than a rating, but it is not a finding that anyone was harmed.

### How many sellers you track have one?

Fifty-seven of the 157 letters are matched to a seller we review. They cover 57 sellers, run by 54 operating companies, and five of those sellers have since closed. That is roughly one in eleven of the sellers we list.

### Did you find a mistake in your own data?

Yes. Four seller reviews stated they had four, five or six warning letters when none of those companies had any letter in the register. The count had been built from a field that also held general FDA notes. It is corrected and guarded, and we verified the fix did not create the opposite error.

> **Correction (September 2026):** this article previously counted 186 letters, 109 of them in 2025, with 87 about unlawful sale. Thirty-eight letters had been entered in our register twice (the thirty-eighth, a MyStart Health letter, was found on September 30). The corrected figures at the time were 148 letters, 71 in 2025 and 54 about unlawful sale; letters added to the register since account for the 157 above. The conclusion is unchanged.

## References

1. GLP Watchdog. FDA warning letter register — 157 letters relevant to GLP-1 selling and compounding, each linked to its FDA source; counts computed September 30, 2026. GLP Watchdog register. 2026. https://glpwatchdog.org/fda-warning-letters
2. U.S. Food and Drug Administration Warning Letter to Online Generic Medicine/www.onlinegenericmedicine.com (MARCS-CMS 737806), September 23, 2026. FDA Warning Letters. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026
3. U.S. Food and Drug Administration Warning Letter to Cheap Medicine Shop/www.cheapmedicineshop.com (MARCS-CMS 737810), September 24, 2026. FDA Warning Letters. 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026

---

Cite as: GLP Watchdog, Ruth Calder, "What the FDA's GLP-1 Warning Letters Say About This Market", published 2026-08-19, updated 2026-11-02. https://glpwatchdog.org/research/what-186-fda-warning-letters-say

Canonical HTML page: https://glpwatchdog.org/research/what-186-fda-warning-letters-say

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
